ArticleMetabolic brain disease2017
Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway.
Article in Metabolic brain disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Effects of inflammation on the kynurenine pathway in schizophrenia - a systematic review.Journal of neuroinflammation · 2020Pooled it
- Development and preliminary psychometric evaluation of a context-specific patient-reported Schizophrenia Disease Burden Scale incorporating socioeconomic and cultural contexts.Scientific reports · 2026Article
- RDoC Mechanisms Underlying Bodily Symptoms in Psychiatry: A Scoping Review.Psychology research and behavior management · 2026Review
- Effects of cerebrolysin on behavioral changes and the tryptophan-kynurenine pathway in the prefrontal cortex of male mice in the ketamine model of schizophrenia.Molecular biology reports · 2025Article
- Clinical Characteristics associated with functional seizures in individuals with psychosis.Schizophrenia research · 2025Article
- Relationship Between Obesity and Depression Considering the Inflammatory Theory.International journal of molecular sciences · 2025Review
- The role of the microbiota-gut-brain axis in schizophrenia: an immunological perspective.Frontiers in immunology · 2025Review
- The novel schizophrenia subgroup "major neurocognitive psychosis" is validated as a distinct class through the analysis of immune-linked neurotoxicity biomarkers and neurocognitive deficits.Brain, behavior, & immunity - health · 2024Article
- Deciphering the interplay between psychopathological symptoms, sensorimotor, cognitive and global functioning: a transdiagnostic network analysis.European archives of psychiatry and clinical neuroscience · 2024Article
- Association between dietary inflammatory index and mental disorders using multilevel modeling with GLIMMIX.Frontiers in nutrition · 2024Article
- Research Progress of Shared Decision-Making in Schizophrenia with Anxiety.Neuropsychiatric disease and treatment · 2024Review
- Changes in Adipokine, Resitin, and BDNF Concentrations in Treatment-Resistant Depression after Electroconvulsive Therapy.Brain sciences · 2023Article
- Somatic symptoms in schizophrenia: Association with socio-demographic and clinical characteristics, disability and quality of life.Indian journal of psychiatry · 2023Article
- PCOS and Depression: Common Links and Potential Targets.Reproductive sciences (Thousand Oaks, Calif.) · 2022Review
- The Role of Kynurenine and Its Metabolites in Comorbid Chronic Pain and Depression.Metabolites · 2022Review
- Association between immunoglobulin A and depression in Chinese older adults: findings from a cross-sectional study.Immunity & ageing : I & A · 2022Article
- Metabolomics: Impact of Comorbidities and Inflammation on Sickness Behaviors for Individuals with Chronic Wounds.Advances in wound care · 2021Review
- Effects of Antidepressant Treatment on Peripheral Biomarkers in Patients with Major Depressive Disorder (MDD).Journal of clinical medicine · 2021Review
- Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: neuro-immune and opioid system correlates.Metabolic brain disease · 2021Article
- Maternal immune activation in rats blunts brain cytokine and kynurenine pathway responses to a second immune challenge in early adulthood.Progress in neuro-psychopharmacology & biological psychiatry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the frequency of physio-somatic symptoms (PS) symptoms in schizophrenia and their relation to positive, negative and affective symptoms; neurocognitive deficits and impairments in the tryptophan catabolite (TRYCAT) pathway. Eighty four patients with schizophrenia and 40 healthy controls were assessed using the 12 item Fibromyalgia and Chronic Fatigue Syndrome Rating scale (FF) and scales for negative and positive symptoms, depression and anxiety. Cognitive functioning was tested using the Cambridge Neuropsychological Test Automated Battery (CANTAB). Other assessments included: immunoglobulin (Ig)A and IgM responses to tryptophan catabolites (TRYCATs), namely quinolinic (QA), 3-OH-kynurenine (3HK), picolinic (PA), xanthurenic (XA) and kynurenic acid (KA) and anthranilic acid (AA). More than 50% of the patients studied had elevated levels of physio-somatic (PS) symptoms, significantly co-occurring with depression and anxiety, but not with negative or positive symptoms. PS symptoms were significantly associated with IgA/IgM responses to TRYCATs, including increased IgA responses to 3 HK, PA and XA, and lowered IgA to QA and AA. Fatigue, muscle pain and tension, autonomic and cognitive symptoms and a flu-like malaise were strongly associated with cognitive impairments in spatial planning and working memory, paired associative learning, visual sustained attention and attention set shifting. PS symptoms in schizophrenia aggregate with depression and anxiety symptoms and may be driven by TRYCAT patterning of IgA/IgM-responses, with IgA indicating mucosal-mediated changes and IgM indicating regulatory functions. As such, the patterning of IgA/IgM responses to TRYCATs may indicate differential TRYCATs regulation of neuronal and glia activity that act to regulate PS signalling in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.